These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18579105)

  • 1. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
    Lin LC; Wang MN; Tsai TH
    Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.
    Slatter JG; Schaaf LJ; Sams JP; Feenstra KL; Johnson MG; Bombardt PA; Cathcart KS; Verburg MT; Pearson LK; Compton LD; Miller LL; Baker DS; Pesheck CV; Lord RS
    Drug Metab Dispos; 2000 Apr; 28(4):423-33. PubMed ID: 10725311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
    Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
    Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.
    Yang XX; Hu ZP; Chan SY; Duan W; Ho PC; Boelsterli UA; Ng KY; Chan E; Bian JS; Chen YZ; Huang M; Zhou SF
    Curr Drug Metab; 2006 May; 7(4):431-55. PubMed ID: 16724931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intraperitoneal administration of CPT-11 in rats--experimental study for pharmacokinetics].
    Nagahama T; Maruyama M; Goseki N
    Gan To Kagaku Ryoho; 2000 Oct; 27(12):1866-9. PubMed ID: 11086432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
    Natsui S; Maruyama M; Ochiai T; Hasegawa K; Takashima I; Nagahama T; Ebuchi M
    Gan To Kagaku Ryoho; 2002 Nov; 29(12):2188-90. PubMed ID: 12484033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
    Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
    Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
    Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
    Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
    Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats.
    Maeda Y; Hamada A; Sanematsu E; Sasaki JI; Yokoo K; Hira A; Saito H
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):953-9. PubMed ID: 19697031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies.
    Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
    Talanta; 2008 Sep; 76(5):1015-21. PubMed ID: 18761148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.
    Chabot GG; Abigerges D; Catimel G; Culine S; de Forni M; Extra JM; Mahjoubi M; Hérait P; Armand JP; Bugat R
    Ann Oncol; 1995 Feb; 6(2):141-51. PubMed ID: 7786822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear pharmacokinetics of CPT-11 in rats.
    Kaneda N; Yokokura T
    Cancer Res; 1990 Mar; 50(6):1721-5. PubMed ID: 2306726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of green tea extract and (-)-epigallocatechin-3-gallate on pharmacokinetics of nadolol in rats.
    Misaka S; Miyazaki N; Fukushima T; Yamada S; Kimura J
    Phytomedicine; 2013 Nov; 20(14):1247-50. PubMed ID: 23920278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
    Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
    Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort.
    Hu ZP; Yang XX; Chen X; Cao J; Chan E; Duan W; Huang M; Yu XQ; Wen JY; Zhou SF
    Curr Drug Metab; 2007 Feb; 8(2):157-71. PubMed ID: 17305494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of the pharmacokinetics and the leukopenia and thrombocytopenia grade after administration of irinotecan and 5-fluorouracil in combination to rats.
    Umezawa T; Kiba T; Numata K; Saito T; Nakaoka M; Shintani S; Sekihara H
    Anticancer Res; 2000; 20(6B):4235-42. PubMed ID: 11205253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.